Nicole Bright, DO
Dermatology · Logan Township, NJNPI 1578722856
Payments from drug & device makers
Across 1,028 payments — averaging $21.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi$4K
- Johnson & Johnson$4K
- LEO Pharma Inc.$3K
- AbbVie$2K
- Novartis$1K
- UCB, Inc.$1K
- plus $8K from 31 others
What the payments were for
- Consulting fees$2,34010%
- Speaking & faculty fees$3,11014%
- Food & beverage$16,04271%
- Education$1,0875%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi | 45 | $4,076 |
| Johnson & Johnson | 118 | $3,779 |
| LEO Pharma Inc. | 113 | $2,565 |
| AbbVie | 112 | $1,532 |
| Novartis | 103 | $1,434 |
| UCB, Inc. | 99 | $1,337 |
| Lilly USA, LLC | 69 | $1,148 |
| Regeneron Healthcare Solutions, Inc. | 47 | $993 |
| Ortho Dermatologics, A Division Of Bausch Health US, LLC | 56 | $783 |
| Incyte Corporation | 39 | $779 |
| Amgen | 36 | $732 |
| E.r. Squibb & Sons, L.L.C. | 49 | $542 |
| Prugen, Inc. Pharmaceuticals | 6 | $426 |
| Sun Pharmaceutical Industries Inc. | 17 | $401 |
| Pfizer | 26 | $394 |
| Galderma Laboratories, L.p. | 19 | $242 |
| Sanofi-aventis U.S. LLC | 2 | $159 |
| Dermavant Sciences, Inc. | 8 | $146 |
| Genentech USA, Inc. | 7 | $133 |
| Arcutis Biotherapeutics, Inc. | 7 | $122 |
| Boehringer Ingelheim | 5 | $117 |
| Biofrontera Inc. | 5 | $94 |
| Bristol Myers Squibb | 5 | $86 |
| Encore Dermatology Inc. | 6 | $81 |
| Mission Pharmacal Company | 4 | $59 |
| Mallinckrodt Hospital Products Inc. | 2 | $55 |
| Organon | 3 | $55 |
| Strata Skin Sciences, Inc. | 4 | $54 |
| Dermira, Inc. | 3 | $50 |
| EPI Health, LLC | 3 | $48 |
| Fresenius Kabi USA, LLC | 3 | $46 |
| VYNE Pharmaceuticals Inc. | 2 | $28 |
| Boston Scientific | 1 | $18 |
| Krystal Biotech Inc | 1 | $18 |
| Taro Pharmaceuticals USA, Inc. | 1 | $18 |
| Journey Medical Corporation | 1 | $14 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$22,578 in reported general payments places this provider in the 85th percentile of 394 dermatology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Skyrizi PenRisankizumab-Rzaa | 21 | $452,849 |
| Dupixent PenDupilumab | 95 | $412,039 |
| TremfyaGuselkumab | 24 | $299,604 |
| OtezlaApremilast | 45 | $222,258 |
| RinvoqUpadacitinib | 25 | $179,598 |
| Cosentyx Sensoready (2 Pens)Secukinumab | 16 | $160,163 |
| Dupixent SyringeDupilumab | 24 | $129,854 |
| AdbryTralokinumab-Ldrm | 31 | $117,471 |
| SotyktuDeucravacitinib | 13 | $90,423 |
| Enbrel MiniEtanercept | 12 | $86,979 |
| SiliqBrodalumab | 12 | $61,635 |
| OpzeluraRuxolitinib Phosphate | 11 | $21,430 |
| ZoryveRoflumilast | 16 | $16,347 |
| Pimecrolimus | 30 | $11,719 |
| Clobetasol Propionate | 129 | $9,650 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonTremfya | $3,779 | $299,60424 claims |
| AmgenOtezla | $732 | $222,25845 claims |
| AbbVieRinvoq | $1,532 | $179,59825 claims |
| LEO Pharma Inc.Adbry | $2,565 | $117,47131 claims |
| E.r. Squibb & Sons, L.L.C.Sotyktu | $542 | $90,42313 claims |
| Ortho Dermatologics, A Division Of Bausch Health US, LLCSiliq | $783 | $61,63512 claims |
| Incyte CorporationOpzelura | $779 | $21,43011 claims |
| Arcutis Biotherapeutics, Inc.Zoryve | $122 | $16,34716 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 394 dermatology providers in New Jersey.
Other dermatology in Logan Township
- Jerry BagelEast Windsor$15.4M
- Jonathan DosikGlen Rock$8.4M
- Omar NoorSomerset$4.6M
- Linda Cappiello-LindsleyHoboken$2.3M
- Winston MoyDenville$1.8M
- Brian KeeganEast Windsor$1.7M
- Jeanine DownieMontclair$1.2M
- Adolfo Fernandez ObregonHoboken$1.1M
- Mital Patel CohenFlorham Park$799K
- Ronald BernardinVoorhees$688K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.